Literature DB >> 10414466

Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo.

T Kielian1, E Nagai, A Ikubo, C A Rasmussen, T Suzuki.   

Abstract

Antigen presenting cells (APC) play an essential role in the generation of tumor-specific immune responses. Dendritic cells are the most potent of APC, capable of activating both antigen-specific CD4+ and CD8+ T cells. Previously, we have described how vaccination of mice with irradiated tumor cells producing granulocyte/macrophage-colony-stimulating factor (GM-CSF) induces tumor-specific immunity capable of protecting mice from a subsequent tumor challenge. The present study extends these findings to examine the types of APC infiltrating vaccination sites and the chemokines responsible for their recruitment. GM-CSF released from genetically engineered tumor cells led to the local accumulation of dendritic cells in and around the vaccination site. Quantification revealed a significant ten-fold increase in the number of dendritic cells infiltrating GM-CSF-producing as opposed to beta-galactosidase-producing (control) vaccination sites. Reverse transcription/polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemical analysis of vaccination sites revealed that MIP-1alpha may be responsible for dendritic cell infiltration into GM-CSF-producing tissues. These findings suggest that GM-CSF may indirectly recruit dendritic cells into vaccination sites through the local production of MIP-1alpha.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10414466     DOI: 10.1007/s002620050556

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Proinflammatory cytokine, chemokine, and cellular adhesion molecule expression during the acute phase of experimental brain abscess development.

Authors:  T Kielian; W F Hickey
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

Review 3.  Intratumoral immunotherapy: using the tumour against itself.

Authors:  Marka R Crittenden; Uma Thanarajasingam; Richard G Vile; Michael J Gough
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

4.  Role of GM-CSF signaling in cell-based tumor immunization.

Authors:  Shohreh Zarei; Frank Schwenter; Patricia Luy; Michel Aurrand-Lions; Philippe Morel; Manfred Kopf; Glenn Dranoff; Nicolas Mach
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

5.  Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

Authors:  Ute E Burkhardt; Ursula Hainz; Kristen Stevenson; Natalie R Goldstein; Mildred Pasek; Masayasu Naito; Di Wu; Vincent T Ho; Anselmo Alonso; Naa Norkor Hammond; Jessica Wong; Quinlan L Sievers; Ana Brusic; Sean M McDonough; Wanyong Zeng; Ann Perrin; Jennifer R Brown; Christine M Canning; John Koreth; Corey Cutler; Philippe Armand; Donna Neuberg; Jeng-Shin Lee; Joseph H Antin; Richard C Mulligan; Tetsuro Sasada; Jerome Ritz; Robert J Soiffer; Glenn Dranoff; Edwin P Alyea; Catherine J Wu
Journal:  J Clin Invest       Date:  2013-08-05       Impact factor: 14.808

6.  Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

Authors:  Miguel-Angel Perales; Jianda Yuan; Sarah Powel; Humilidad F Gallardo; Teresa S Rasalan; Christina Gonzalez; Gregor Manukian; Jian Wang; Yan Zhang; Paul B Chapman; Susan E Krown; Philip O Livingston; Samuel Ejadi; Katherine S Panageas; Manuel E Engelhorn; Stephanie L Terzulli; Alan N Houghton; Jedd D Wolchok
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.